245 related articles for article (PubMed ID: 33117288)
1. The Clinical Value and Interpretation of Anti-Müllerian Hormone in Women With Cancer.
Anderson RA; Su HI
Front Endocrinol (Lausanne); 2020; 11():574263. PubMed ID: 33117288
[TBL] [Abstract][Full Text] [Related]
2. Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review.
Anderson RA; Cameron D; Clatot F; Demeestere I; Lambertini M; Nelson SM; Peccatori F
Hum Reprod Update; 2022 May; 28(3):417-434. PubMed ID: 35199161
[TBL] [Abstract][Full Text] [Related]
3. Anti-müllerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy.
Fréour T; Barrière P; Masson D
Eur J Cancer; 2017 Mar; 74():1-8. PubMed ID: 28135602
[TBL] [Abstract][Full Text] [Related]
4. The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer.
Anderson RA; Mansi J; Coleman RE; Adamson DJA; Leonard RCF
Eur J Cancer; 2017 Dec; 87():58-64. PubMed ID: 29117576
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer.
Anderson RA; Rosendahl M; Kelsey TW; Cameron DA
Eur J Cancer; 2013 Nov; 49(16):3404-11. PubMed ID: 23968732
[TBL] [Abstract][Full Text] [Related]
6. Ovarian reserve assessment in users of oral contraception seeking fertility advice on their reproductive lifespan.
Birch Petersen K; Hvidman HW; Forman JL; Pinborg A; Larsen EC; Macklon KT; Sylvest R; Andersen AN
Hum Reprod; 2015 Oct; 30(10):2364-75. PubMed ID: 26311148
[TBL] [Abstract][Full Text] [Related]
7. Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations.
Phillips KA; Collins IM; Milne RL; McLachlan SA; Friedlander M; Hickey M; Stern C; Hopper JL; Fisher R; Kannemeyer G; Picken S; Smith CD; Kelsey TW; Anderson RA;
Hum Reprod; 2016 May; 31(5):1126-32. PubMed ID: 27094481
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment serum anti-müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer.
Anderson RA; Cameron DA
J Clin Endocrinol Metab; 2011 May; 96(5):1336-43. PubMed ID: 21325458
[TBL] [Abstract][Full Text] [Related]
9. Uses of anti-Müllerian hormone (AMH) measurement before and after cancer treatment in women.
Dunlop CE; Anderson RA
Maturitas; 2015 Mar; 80(3):245-50. PubMed ID: 25596814
[TBL] [Abstract][Full Text] [Related]
10. The role of antimullerian hormone in assessing ovarian damage from chemotherapy, radiotherapy and surgery.
Wong QHY; Anderson RA
Curr Opin Endocrinol Diabetes Obes; 2018 Dec; 25(6):391-398. PubMed ID: 30299433
[TBL] [Abstract][Full Text] [Related]
11. Anti-Müllerian hormone and assessment of ovarian reserve after ovarian toxic treatment: a systematic narrative review.
Iwase A; Nakamura T; Nakahara T; Goto M; Kikkawa F
Reprod Sci; 2015 May; 22(5):519-26. PubMed ID: 25228631
[TBL] [Abstract][Full Text] [Related]
12. The physiology and clinical utility of anti-Mullerian hormone in women.
Dewailly D; Andersen CY; Balen A; Broekmans F; Dilaver N; Fanchin R; Griesinger G; Kelsey TW; La Marca A; Lambalk C; Mason H; Nelson SM; Visser JA; Wallace WH; Anderson RA
Hum Reprod Update; 2014; 20(3):370-85. PubMed ID: 24430863
[TBL] [Abstract][Full Text] [Related]
13. Gonadotrophin-releasing hormone agonists for fertility preservation: unraveling the enigma?
Hasky N; Uri-Belapolsky S; Goldberg K; Miller I; Grossman H; Stemmer SM; Ben-Aharon I; Shalgi R
Hum Reprod; 2015 May; 30(5):1089-101. PubMed ID: 25796551
[TBL] [Abstract][Full Text] [Related]
14. Ovarian reserve in breast cancer: assessment with anti-Müllerian hormone.
Hamy AS; Porcher R; Cuvier C; Giacchetti S; Schlageter MH; Coussieu C; Gronier H; Feugeas JP; Adoui N; Lacorte JM; Poirot C; Habdous M; Espié M
Reprod Biomed Online; 2014 Nov; 29(5):573-80. PubMed ID: 25246112
[TBL] [Abstract][Full Text] [Related]
15. Predicting Ovarian Activity in Women Affected by Early Breast Cancer: A Meta-Analysis-Based Nomogram.
Barnabei A; Strigari L; Marchetti P; Sini V; De Vecchis L; Corsello SM; Torino F
Oncologist; 2015 Oct; 20(10):1111-8. PubMed ID: 26341758
[TBL] [Abstract][Full Text] [Related]
16. Female adolescents and young women previously treated for pediatric malignancies: assessment of ovarian reserve and gonadotoxicity risk stratification for early identification of patients at increased infertility risk.
Parissone F; Di Paola R; Balter R; Garzon S; Zaffagnini S; Neri M; Vitale V; Tridello G; Cesaro S
J Pediatr Endocrinol Metab; 2021 Jan; 34(1):25-33. PubMed ID: 33068384
[TBL] [Abstract][Full Text] [Related]
17. Anti-Müllerian hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: a prospective study.
Brougham MF; Crofton PM; Johnson EJ; Evans N; Anderson RA; Wallace WH
J Clin Endocrinol Metab; 2012 Jun; 97(6):2059-67. PubMed ID: 22472563
[TBL] [Abstract][Full Text] [Related]
18. Influence of adjuvant chemotherapy on anti-Müllerian hormone in women below 35 years treated for early breast cancer.
Perdrix A; Saint-Ghislain M; Degremont M; David M; Khaznadar Z; Loeb A; Leheurteur M; Di Fiore F; Clatot F
Reprod Biomed Online; 2017 Oct; 35(4):468-474. PubMed ID: 28652099
[TBL] [Abstract][Full Text] [Related]
19. Utility of Ovarian Reserve Screening with Anti-Müllerian Hormone for Reproductive Age Women Deferring Pregnancy.
Grossman LC; Safier LZ; Kline MD; Chan CW; Lobo RA; Sauer MV; Douglas NC
J Womens Health (Larchmt); 2017 Apr; 26(4):345-351. PubMed ID: 27906603
[TBL] [Abstract][Full Text] [Related]
20. Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial.
Wenners A; Grambach J; Koss J; Maass N; Jonat W; Schmutzler A; Mundhenke C
BMC Cancer; 2017 Sep; 17(1):632. PubMed ID: 28877720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
